Anti-neutral glycolipid antibodies in encephalomyeloradiculoneuropathy

Sayuri Shima, Naoki Kawamura, Tomomasa Ishikawa, Hiromi Masuda, Chihiro Iwahara, Yoshiki Niimi, Akihiro Ueda, Kazuhiza Iwabuchi, Tatsuro Mutoh

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objective: The aim of this study was to review 4 patients with encephalomyeloradiculoneuropathy (EMRN) and assess for autoantibodies against neutral glycolipids. Methods: We studied the progression of clinical, radiologic, neurophysiologic, and CSF findings, as well as anti-neutral glycolipid antibodies in sera. Results: All patients developed acute or subacute motor weakness and impaired consciousness. Their CSF showed pleocytosis and high immunoglobulin G concentrations. MRI revealed lesions in the brain and spinal cord. Neurophysiologic examinations indicated dysfunction of the spinal cord, nerve roots, and peripheral nerves. Steroid pulsed immunotherapy and/or high dose of IV immunoglobulin replacement therapy resulted in clear and often dramatic clinical improvements. Reactivity to anti-neutral glycolipid antibodies was positive in all patients with acute EMRN but not in the recovery phase. Forty-seven age-matched patients with other neurologic disorders and 28 age-matched healthy volunteers tested negative for reactivity to anti-neutral glycolipid antibodies. Conclusion: The resolution of radiologic and neurologic abnormalities and altered autoantibody titers against neutral glycolipids after immunotherapy suggest that EMRN is caused by an immune-mediated mechanism. These autoantibodies may be useful biomarkers for EMRN.

Original languageEnglish
Pages (from-to)114-118
Number of pages5
JournalNeurology
Volume82
Issue number2
DOIs
Publication statusPublished - 14-01-2014

Fingerprint

Glycolipids
Antibodies
Autoantibodies
Immunotherapy
Spinal Cord
Nervous System Malformations
Passive Immunization
Spinal Nerve Roots
Intravenous Immunoglobulins
Leukocytosis
Nervous System Diseases
Consciousness
Peripheral Nerves
Healthy Volunteers
Immunoglobulin G
Biomarkers
Steroids
Brain
Serum

All Science Journal Classification (ASJC) codes

  • Clinical Neurology

Cite this

Shima, S., Kawamura, N., Ishikawa, T., Masuda, H., Iwahara, C., Niimi, Y., ... Mutoh, T. (2014). Anti-neutral glycolipid antibodies in encephalomyeloradiculoneuropathy. Neurology, 82(2), 114-118. https://doi.org/10.1212/WNL.0000000000000015
Shima, Sayuri ; Kawamura, Naoki ; Ishikawa, Tomomasa ; Masuda, Hiromi ; Iwahara, Chihiro ; Niimi, Yoshiki ; Ueda, Akihiro ; Iwabuchi, Kazuhiza ; Mutoh, Tatsuro. / Anti-neutral glycolipid antibodies in encephalomyeloradiculoneuropathy. In: Neurology. 2014 ; Vol. 82, No. 2. pp. 114-118.
@article{2e63fb849267450ab43ef010d16f88ee,
title = "Anti-neutral glycolipid antibodies in encephalomyeloradiculoneuropathy",
abstract = "Objective: The aim of this study was to review 4 patients with encephalomyeloradiculoneuropathy (EMRN) and assess for autoantibodies against neutral glycolipids. Methods: We studied the progression of clinical, radiologic, neurophysiologic, and CSF findings, as well as anti-neutral glycolipid antibodies in sera. Results: All patients developed acute or subacute motor weakness and impaired consciousness. Their CSF showed pleocytosis and high immunoglobulin G concentrations. MRI revealed lesions in the brain and spinal cord. Neurophysiologic examinations indicated dysfunction of the spinal cord, nerve roots, and peripheral nerves. Steroid pulsed immunotherapy and/or high dose of IV immunoglobulin replacement therapy resulted in clear and often dramatic clinical improvements. Reactivity to anti-neutral glycolipid antibodies was positive in all patients with acute EMRN but not in the recovery phase. Forty-seven age-matched patients with other neurologic disorders and 28 age-matched healthy volunteers tested negative for reactivity to anti-neutral glycolipid antibodies. Conclusion: The resolution of radiologic and neurologic abnormalities and altered autoantibody titers against neutral glycolipids after immunotherapy suggest that EMRN is caused by an immune-mediated mechanism. These autoantibodies may be useful biomarkers for EMRN.",
author = "Sayuri Shima and Naoki Kawamura and Tomomasa Ishikawa and Hiromi Masuda and Chihiro Iwahara and Yoshiki Niimi and Akihiro Ueda and Kazuhiza Iwabuchi and Tatsuro Mutoh",
year = "2014",
month = "1",
day = "14",
doi = "10.1212/WNL.0000000000000015",
language = "English",
volume = "82",
pages = "114--118",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

Shima, S, Kawamura, N, Ishikawa, T, Masuda, H, Iwahara, C, Niimi, Y, Ueda, A, Iwabuchi, K & Mutoh, T 2014, 'Anti-neutral glycolipid antibodies in encephalomyeloradiculoneuropathy', Neurology, vol. 82, no. 2, pp. 114-118. https://doi.org/10.1212/WNL.0000000000000015

Anti-neutral glycolipid antibodies in encephalomyeloradiculoneuropathy. / Shima, Sayuri; Kawamura, Naoki; Ishikawa, Tomomasa; Masuda, Hiromi; Iwahara, Chihiro; Niimi, Yoshiki; Ueda, Akihiro; Iwabuchi, Kazuhiza; Mutoh, Tatsuro.

In: Neurology, Vol. 82, No. 2, 14.01.2014, p. 114-118.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Anti-neutral glycolipid antibodies in encephalomyeloradiculoneuropathy

AU - Shima, Sayuri

AU - Kawamura, Naoki

AU - Ishikawa, Tomomasa

AU - Masuda, Hiromi

AU - Iwahara, Chihiro

AU - Niimi, Yoshiki

AU - Ueda, Akihiro

AU - Iwabuchi, Kazuhiza

AU - Mutoh, Tatsuro

PY - 2014/1/14

Y1 - 2014/1/14

N2 - Objective: The aim of this study was to review 4 patients with encephalomyeloradiculoneuropathy (EMRN) and assess for autoantibodies against neutral glycolipids. Methods: We studied the progression of clinical, radiologic, neurophysiologic, and CSF findings, as well as anti-neutral glycolipid antibodies in sera. Results: All patients developed acute or subacute motor weakness and impaired consciousness. Their CSF showed pleocytosis and high immunoglobulin G concentrations. MRI revealed lesions in the brain and spinal cord. Neurophysiologic examinations indicated dysfunction of the spinal cord, nerve roots, and peripheral nerves. Steroid pulsed immunotherapy and/or high dose of IV immunoglobulin replacement therapy resulted in clear and often dramatic clinical improvements. Reactivity to anti-neutral glycolipid antibodies was positive in all patients with acute EMRN but not in the recovery phase. Forty-seven age-matched patients with other neurologic disorders and 28 age-matched healthy volunteers tested negative for reactivity to anti-neutral glycolipid antibodies. Conclusion: The resolution of radiologic and neurologic abnormalities and altered autoantibody titers against neutral glycolipids after immunotherapy suggest that EMRN is caused by an immune-mediated mechanism. These autoantibodies may be useful biomarkers for EMRN.

AB - Objective: The aim of this study was to review 4 patients with encephalomyeloradiculoneuropathy (EMRN) and assess for autoantibodies against neutral glycolipids. Methods: We studied the progression of clinical, radiologic, neurophysiologic, and CSF findings, as well as anti-neutral glycolipid antibodies in sera. Results: All patients developed acute or subacute motor weakness and impaired consciousness. Their CSF showed pleocytosis and high immunoglobulin G concentrations. MRI revealed lesions in the brain and spinal cord. Neurophysiologic examinations indicated dysfunction of the spinal cord, nerve roots, and peripheral nerves. Steroid pulsed immunotherapy and/or high dose of IV immunoglobulin replacement therapy resulted in clear and often dramatic clinical improvements. Reactivity to anti-neutral glycolipid antibodies was positive in all patients with acute EMRN but not in the recovery phase. Forty-seven age-matched patients with other neurologic disorders and 28 age-matched healthy volunteers tested negative for reactivity to anti-neutral glycolipid antibodies. Conclusion: The resolution of radiologic and neurologic abnormalities and altered autoantibody titers against neutral glycolipids after immunotherapy suggest that EMRN is caused by an immune-mediated mechanism. These autoantibodies may be useful biomarkers for EMRN.

UR - http://www.scopus.com/inward/record.url?scp=84895749518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895749518&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000000015

DO - 10.1212/WNL.0000000000000015

M3 - Article

VL - 82

SP - 114

EP - 118

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 2

ER -

Shima S, Kawamura N, Ishikawa T, Masuda H, Iwahara C, Niimi Y et al. Anti-neutral glycolipid antibodies in encephalomyeloradiculoneuropathy. Neurology. 2014 Jan 14;82(2):114-118. https://doi.org/10.1212/WNL.0000000000000015